Goldline Pharmaceutical Ltd (544759)
சுருக்கம்
The board meets on 14 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 14 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q4 FY26
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 14 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Goldline Pharmaceutical Ltd-இன் இயக்குநர் குழுக் கூட்டம் 14 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q4 FY26, Goldline Pharmaceutical's revenue was ₹17.3 Cr, and net profit ₹2.8 Cr; the operating margin was 24.9%.
| Q4 FY26 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹17.3 | — | — |
| செயல்பாட்டு லாபம் | ₹4.3 | — | — |
| நிகர லாபம் | ₹2.8 | — | — |
| EPS (₹) | 4.00 | — | — |
| செயல்பாட்டு லாப வரம்பு | 24.9% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Goldline Pharmaceutical Ltd has received a disclosure under SEBI SAST Regulation 29(2) regarding insider share purchases. Promoter and Whole Time Director Mr. Swapan Khandelwal acquired 78,000 equity shares through the open market on August 28, 2026. This transaction represents approximately 0.81% of the company's total issued and paid-up share capital.
- Promoter & Whole Time Director Swapan Khandelwal acquired 78,000 equity shares
- Acquisition represents 0.81% of total paid-up share capital
- Transaction conducted via open market on August 28, 2026
- Disclosure filed pursuant to Regulation 29(2) of SEBI SAST Regulations, 2011
Goldline Pharmaceutical has announced its 22nd Annual General Meeting (AGM) scheduled for August 29, 2026. In preparation, the company will close its Register of Members and Share Transfer Books from August 23 to August 29, 2026. The cut-off date for determining shareholder eligibility for the AGM is August 22, 2026. This is a standard regulatory procedure for listed entities to facilitate shareholder participation in the annual meeting.
- 22nd Annual General Meeting scheduled for Saturday, August 29, 2026, at 4:00 P.M.
- Book closure period defined from August 23, 2026, to August 29, 2026 (7 days inclusive).
- Cut-off date for member eligibility set as Saturday, August 22, 2026.
- Company's paid-up capital is confirmed at ₹9,60,00,000 consisting of 96 lakh equity shares.
Goldline Pharmaceutical has submitted its first Annual Report post-listing for FY 2025-26. The company reported a revenue of ₹31.2 Cr and a net profit of ₹4.12 Cr for the full year, showing growth from ₹28.01 Cr and ₹2.83 Cr respectively in FY25. The report outlines a portfolio of 146 products across five specialized divisions. The 22nd Annual General Meeting (AGM) is scheduled for August 29, 2026, to adopt financial statements and declare preference share dividends.
- FY26 Revenue reached ₹31.2 Cr, a 11.4% increase from ₹28.01 Cr in FY25
- Net Profit for FY26 stood at ₹4.12 Cr, up from ₹2.83 Cr in the previous year
- The company manages a portfolio of 146 products across 5 specialized divisions (Pharma, Cardinal, Aayushman, In Life, Wellness)
- Successfully listed on the BSE SME Platform on May 19, 2026
- AGM scheduled for August 29, 2026, with a shareholder cut-off date of August 22, 2026
Goldline Pharmaceutical has issued a notice for its 22nd AGM on August 29, 2026, proposing significant financial resolutions. The company seeks shareholder approval to borrow up to ₹200 Cr from directors, with a provision to convert these unsecured loans into equity shares. This limit is highly material, representing approximately 6.4x the company's FY26 revenue of ₹31.2 Cr. Additionally, the company is seeking a ₹200 Cr limit for loans and guarantees to entities where directors are interested, alongside ratifying material related party transactions.
- Proposed borrowing limit of ₹200 Cr from directors, which is ~14x the current net worth of ₹14 Cr
- Provision for converting director loans into fully paid-up equity shares at SEBI-regulated prices
- Approval sought for loans, investments, or guarantees up to ₹200 Cr under Section 185 for subsidiaries/associates
- Ratification of material related party transactions with Activista Healthcare, Nucleage Pharma, and Numerius Healthcare
- FY26 annual revenue stood at ₹31.2 Cr with a net profit of ₹4.12 Cr
Mr. Prashant Shrikrishna Karkare, an Executive Director of Goldline Pharmaceutical Ltd, acquired 27,000 equity shares on July 28, 2026. This transaction represents 0.28% of the company's total issued and paid-up share capital and was conducted through the open market. Insider buying of this nature is typically viewed as a sign of management confidence in the company's valuation and future prospects. The company reported a net profit of ₹4.12 cr on a revenue of ₹31.2 cr for FY26.
- Acquisition of 27,000 equity shares by Executive Director Prashant Shrikrishna Karkare
- The purchase represents 0.28% of the total issued and paid-up share capital
- Transaction executed on July 28, 2026, through the open market
- Company reported FY26 revenue of ₹31.2 cr and PAT of ₹4.12 cr
Goldline Pharmaceutical Ltd has appointed M/s. Avinash Prakash Gandhewar as its Secretarial Auditor for the financial year 2025-26. The appointment was approved by the Board of Directors in a meeting held on July 14, 2026. The auditor is a peer-reviewed firm with expertise in Company Law, Securities Laws, and SME IPOs. This is a standard regulatory compliance filing under SEBI (LODR) Regulations.
- Appointment of M/s. Avinash Prakash Gandhewar as Secretarial Auditor for FY 2025-26
- Board approval granted on July 14, 2026, for the audit of the period ending March 31, 2026
- The auditor holds Membership No. FCS 11197 and is a peer-reviewed firm
- Scope of audit includes compliance with Company Law, FEMA, and Securities Laws
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
